IP Library Patent Application 13319685
Patent Application
App. No. 13/319,685

Methods For Whole-Cell Analysis Of Gram-Positive Bacteria

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/319,685
Abstract

This application pertains to methods for the whole-cell analysis of gram-positive bacteria. The methods are capable of making a determination of whether or not a sample (e.g. a clinical sample) comprises one or more select gram-positive bacteria as well as, for example, whether or not none, some or all of said select gram-positive bacteria in said sample, or possibly other bacteria in said sample, possess a select trait or traits of interest. In some embodiments, the methods can be used to determine methicillin-resistant (the select trait) staphylococcus aureus (the select gram-positive bacteria), coagulase-negative staphylococci (another select gram-positive bacteria) and/or methicillin-sensitive staphylococcus aureus (MSSA) in said sample. The whole-cell analysis can be performed, for example, by in-situ hybridization (ISH), fluorescence in-situ hybridization (FISH), immunocytochemistry (ICC), or any combination of two or more of the foregoing.

Claims (56)

1 . A method comprising:

a) contacting a sample comprising bacteria with a chromosomal DNA-, mRNA- and/or native plasmid-directed labeled probe or probes capable of determining chromosomal DNA, mRNA and/or plasmid nucleic acid associated with a select trait that may be possessed by a select gram-positive bacteria and/or in other bacteria of said sample; and

b) determining bacteria of said sample that possess said select trait;

wherein,

i) said method is practiced on whole-cells; ii) said chromosomal DNA-, mRNA- and/or native plasmid-directed labeled probe or probes is/are each labeled with a single label or with two labels; and (iii) the method is practiced without use of in-situ PCR.

2 . The method of claim 1 , further comprising contacting the sample with a bacteria-directed probe or probes capable of determining the select gram-positive bacteria in said sample and determining one or more of said select gram-positive bacteria in said sample.

3 . The method of any of claim 1 , wherein step (a) is practiced with only mRNA-directed labeled probe or probes.

4 . The method of claim 3 , wherein the method is practiced with a mixture of mRNA-directed labeled probes.

5 . The method of claim 1 , wherein said method is practiced without signal amplification of said label of said chromosomal DNA-, mRNA- and/or native plasmid-directed labeled probe or probes.

6 . The method of claim 2 , wherein said bacteria-directed probe or probes is/are rRNA-directed.

7 . The method of claim 2 , wherein said bacteria-directed probe or probes is/are antibody-based.

8 . The method of claim 2 , wherein said bacteria-directed probe or probes is/are mRNA-directed.

9 . The method of claim 2 , wherein said bacteria-directed probe or probes is/are labeled with a label or labels.

10 . The method of claim 9 , wherein each bacteria-directed probe is labeled with a single label or with two labels.

11 . The method of claim 2 , further comprising determining select gram-positive bacteria of said sample that also possess said select trait.

12 . The method of claim 1 , further comprising, prior to performing step (a), contacting said sample with a mRNA inducing reagent or reagents.

13 . The method of claim 1 , wherein all labels are fluorescent labels and said method is a fluorescent in-situ hybridization (FISH) assay.

14 . The method of claim 1 , wherein no pre-hybridization step is performed.

15 . The method of claim 1 , further comprising treating said sample with an RNase inhibitor prior to performing step (a).

16 . The method of claim 1 , wherein said select trait is associated with 1) antibiotic resistance; 2) toxin production; and/or 3) virulence.

17 . The method claim 16 , wherein said select trait is determined by determining the bacteria that possess: 1) a mecA gene or vanA or vanB gene; 2) a tcdB gene; and/or 3) a lukF or lukS gene, respectively.

18 . The method of claim 1 wherein the method is practiced without contacting the sample with a cell permeabilizing reagent or reagents.

19 . The method of claim 1 , wherein said method further comprises contacting said sample with; 1) a second bacteria-directed probe or probes capable of determining a second select gram-positive bacteria in said sample; and/or 2) a second chromosomal DNA, mRNA-directed and/or native plasmid-directed labeled probe or probes capable of determining chromosomal DNA, mRNA and/or plasmid nucleic acid associated with a second select trait that may be present in any bacteria of said sample.

20 . The method of claim 1 , wherein said label or labels of said chromosomal DNA-, mRNA- and/or native plasmid-directed labeled probe or probes is/are determined directly.

21 . The method of claim 1 , wherein said chromosomal DNA-, mRNA- and/or native plasmid-directed labeled probe or probes is/are PNA.

22 . (canceled)

23 . A method comprising:

a) contacting a sample with:

i) a bacteria-directed probe or probes capable of determining S. aureus bacteria in said sample; and

ii) a chromosomal DNA and/or mRNA-directed labeled probe or probes capable of determining methicillin-resistance in bacteria of said sample;

b) determining one or more S. aureus bacteria in said sample; and

c) determining one or more bacteria of said sample that possess methicillin-resistance;

wherein,

i) said method is practiced on whole-cells; ii) steps (b) and (c) are carried out in either order or simultaneously; and (iii) the method is practiced without use of in-situ PCR.

24 - 46 . (canceled)

47 . A method comprising:

a) contacting a sample comprising bacteria with a chromosomal DNA-, mRNA- and/or native plasmid-directed labeled probe or probes capable of determining chromosomal DNA, mRNA and/or plasmid nucleic acid associated with a select trait that may be possessed by a select gram-positive bacteria and/or in other bacteria of said sample; and

b) determining bacteria of said sample that possess said select trait;

wherein,

i) said method is practiced on whole-cells; ii) said method is practiced without treating the sample with an enzyme-based cell permeabilizing reagent or reagents.

48 - 50 . (canceled)

51 . A mixture comprising mRNA-directed probes capable of determining a select trait known to exist in pram-positive bacteria.

52 - 54 . (canceled)

55 . A method comprising:

a) contacting a sample with a chromosomal DNA and/or mRNA-directed labeled probe or probes capable of determining methicillin-resistance in bacteria of said sample; and

b) determining one or more bacteria of said sample that possess methicillin-resistance;

wherein, (i) said method is practiced on whole-cells and (ii) the method is practiced without use of in-situ PCR.

56 - 57 . (canceled)

58 . A method comprising:

a) contacting a sample with:

i) a bacteria-directed probe or probes capable of determining a select gram-positive bacteria in said sample; and

ii) a chromosomal DNA-, mRNA- and/or native plasmid-directed labeled probe or probes capable of determining chromosomal DNA, mRNA and/or plasmid nucleic acid associated with a select trait that may be possessed by said select gram-positive bacteria and/or in other bacteria of said sample;

b) determining one or more of said select gram-positive bacteria in said sample; and

c) determining bacteria of said sample that possess said select trait;

wherein,

i) said method is practiced on whole-cells; ii) steps (b) and (c) are carried out in either order or simultaneously; iii) said chromosomal DNA-, mRNA- and/or native plasmid-directed labeled probe or probes each comprise a single label or two labels; and the method is practiced without use of in-situ PCR.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 3, 2021
From: MERCK GLOBAL HEALTH INNOVATION FUND, LLC
To: OPGEN, INC.; ADVANDX, INC.
Reel/Frame 055209/0242 →
SECURITY INTEREST Recorded Aug 17, 2015
From: OPGEN, INC.; ADVANDX, INC.
To: MERCK GLOBAL HEALTH INNOVATION FUND, LLC
Reel/Frame 036377/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2011
From: STENDER, HENRIK; TRNOVSKY, JAN; KLIMAS, LISA L; RASMUSSEN, ANNE K. I.
To: ADVANDX, INC.
Reel/Frame 027203/0358 →